TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
HHS announced an update to the National Plan to Address Alzheimer’s Disease and Related Dementias on October 22, 2026. The revised plan sets four goals and is accompanied by research investments, a new FDA prevention accelerator, and expanded support for caregivers and elder justice professionals.
The U.S. Department of Health and Human Services announced an update Thursday to the National Plan to Address Alzheimer’s Disease and Related Dementias, reshaping its goals around prevention, earlier detection, treatment development and support for caregivers. The announcement also included federal research initiatives and a new FDA program focused on preventing or delaying Alzheimer’s-related cognitive decline.
The updated plan replaces six historical goals with four: promoting dementia risk reduction; accelerating ways to prevent and treat Alzheimer’s disease and dementia; adding dementia care components; and strengthening caregiver support. HHS said the revisions put greater emphasis on reducing dementia risk across the lifespan and on earlier intervention.
Among the research initiatives, the Advanced Research Projects Agency for Health (ARPA-H) announced a collective investment of up to $48.8 million in projects. Up to $41 million is designated for Mass General Brigham researchers to lead a multi-institutional platform trial testing drugs already approved for other conditions, as well as supplements, plant-derived products and other compounds, for potential use against Alzheimer’s. ARPA-H will also award $2.75 million to support work at the University of California, San Francisco, complementing existing research on sleep-related risks and early protein dysfunction.
The FDA also launched an Alzheimer’s Prevention Accelerator within its new Neuroscience Advancement and Innovation Nexus program. HHS described the accelerator as a way to foster approaches to prevent or delay cognitive decline due to Alzheimer’s. Separately, the Administration for Community Living plans to expand brain-health resources and training for elder justice professionals, including lawyers and social workers who work to prevent abuse and financial exploitation of older adults.
Research, Prevention and Care Priorities
The update links national policy goals with a set of research and service initiatives. The planned platform trial could test multiple kinds of interventions, including medicines developed for other conditions, but the announcement does not establish that any of them prevent or treat Alzheimer’s. Their potential benefit would need to be determined through research.
The plan also addresses needs beyond drug development. HHS listed initiatives to expand dementia training and screening, create behavioral-health and crisis-response resources for people with cognitive decline, strengthen public-health approaches, examine diagnostic delays and the economic burden of dementia, review prevention evidence, and test a lifestyle intervention for people with mild cognitive impairment. These efforts touch research, care and support for families, though the announcement provides limited detail on their timelines and reach.
The Alzheimer’s Association welcomed the focus on innovation but said access to advances matters. The group pointed to the bipartisan Alzheimer’s Screening and Prevention Act, or ASAP Act, and Medicare beneficiaries’ access to blood-based biomarker testing. Its statement reflects an advocacy position; the HHS announcement does not say that the legislation has passed or that Medicare coverage has changed.
blood-based biomarker testing for Alzheimer's
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
How the National Plan Is Changing
The National Plan to Address Alzheimer’s Disease and Related Dementias is the federal framework referenced in HHS’s announcement. This update changes its goal structure from six historical goals to four broader priorities, placing risk reduction and faster development of prevention and treatment approaches prominently in the plan.
The announcement groups several federal activities under the updated direction, including ARPA-H research funding, the FDA accelerator, and expanded training and resources through the Administration for Community Living. HHS also described work on screening, care, public health and prevention evidence. The source report does not provide a full implementation schedule or detailed funding totals for every initiative, so the listed activities should not be read as having identical status or budgets.
“Under President Trump, HHS is shifting the national strategy toward prevention, earlier detection, and faster development of better diagnostics and treatments.”
— HHS Secretary Robert F. Kennedy Jr., in an HHS news release
cognitive screening tools for early detection
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Funding, Timelines and Access Details
The announcement does not set out a complete timeline for carrying out the updated plan, explain how progress against the four goals will be measured, or specify when the platform trial will begin and report results. The ARPA-H figures are described as investments of up to $48.8 million collectively and up to $41 million for the Mass General Brigham-led work; the source report does not provide a full breakdown of when funds will be distributed.
It is also unclear which proposed interventions will move forward in trials, what outcomes they will test, or whether any will prove effective or safe. HHS did not detail eligibility, coverage or implementation plans for the listed screening, training and care initiatives. The announcement does not establish changes to Medicare coverage for blood-based biomarker testing, an issue raised separately by the Alzheimer’s Association.
dementia caregiver support products
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Trial Plans and Program Rollout
The next practical milestones are likely to include further details from ARPA-H and the research institutions about trial design, participating sites, enrollment and study timelines, as well as information from the FDA about the accelerator’s work. HHS agencies will also need to clarify how the plan’s broader training, screening, care and public-health activities will be delivered and tracked.
For now, the announcement establishes the revised policy priorities and identifies initiatives intended to support them, but it does not report results from the newly described projects. The Alzheimer’s Association has urged Congress to advance the ASAP Act; whether lawmakers act on that proposal, and what that would mean for Medicare beneficiaries, remains unresolved.
Alzheimer's prevention supplements
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What changed in the updated national dementia plan?
HHS replaced six historical goals with four, focused on risk reduction, accelerating prevention and treatment, dementia care, and caregiver support.
How much research funding did ARPA-H announce?
ARPA-H announced a collective investment of up to $48.8 million. Up to $41 million is for a Mass General Brigham-led platform trial, and $2.75 million will support Alzheimer’s research at the University of California, San Francisco.
What will the Alzheimer’s platform trial test?
The planned multi-institutional trial will test drugs approved for other conditions that may be repurposed, along with supplements, plant-derived products and other compounds. The announcement does not identify which candidates will be tested or provide a start date or results.
Does the update change Medicare coverage for Alzheimer’s tests?
The announcement does not state that Medicare coverage has changed. The Alzheimer’s Association separately called on Congress to pass the bipartisan ASAP Act and said access to blood-based biomarker testing should be part of the discussion.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
